Skip to main content
رجوع
INBX logo

Inhibrx Biosciences, Inc.

جودة البيانات: 100%
INBX
NASDAQ Healthcare Biotechnology
KWD 63.12
▼ KWD 1.51 (-2.34%)
القيمة السوقية: 922.00M
نطاق اليوم
KWD 59.98 KWD 63.39
نطاق 52 أسبوعًا
KWD 10.81 KWD 94.57
حجم التداول
242,172
متوسط 50 يوم / 200 يوم
KWD 75.51 / KWD 51.38
الإغلاق السابق
KWD 64.63

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -6.6 0.3
P/B 115.4 2.9
ROE % -197.9 3.7
Net Margin % -10773.5 3.8
Rev Growth 5Y % -34.6 10.0
D/E 13.4 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 1.750
KWD 1.750 – KWD 1.750
190 M 1
FY2029 KWD 0.220
KWD 0.220 – KWD 0.220
130 M 1
FY2028 -KWD 0.950
-KWD 0.950 – -KWD 0.950
98 M 1

النقاط الرئيسية

Revenue declined -34.64% annually over 5 years
Earnings declined -108.30% over the past year
Debt/Equity of 13.39 — high leverage
Negative free cash flow of -129.83M
PEG of 0.08 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 584.64%

النمو

Revenue Growth (5Y)
-34.64%
Revenue (1Y)550.00%
Earnings (1Y)-108.30%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-197.85%
ROIC-88.06%
Net Margin-10773.46%
Op. Margin-10386.54%

الأمان

Debt / Equity
13.39
Current Ratio3.93
Interest Coverage-11.07

التقييم

P/E Ratio
-6.58
P/B Ratio115.35
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 550.00% Revenue Growth (3Y) -15.02%
Earnings Growth (1Y) -108.30% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -34.64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.30M Net Income (TTM) -140.06M
ROE -197.85% ROA -95.62%
Gross Margin -91.00% Operating Margin -10386.54%
Net Margin -10773.46% Free Cash Flow (TTM) -129.83M
ROIC -88.06% FCF Growth (3Y) N/A
Safety
Debt / Equity 13.39 Current Ratio 3.93
Interest Coverage -11.07 Dividend Yield 0.00%
Valuation
P/E Ratio -6.58 P/B Ratio 115.35
P/S Ratio 709.23 PEG Ratio 0.08
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 922.00M Enterprise Value 904.79M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.30M 200,000.0 1.80M 2.19M 7.13M
Net Income -140.06M 1.69B -241.36M -145.23M -81.77M
EPS (Diluted) -9.04 116.58 -5.12 -3.62 -2.15
Gross Profit -1.18M -2.09M 609,000.0 -107.99M 4.44M
Operating Income -135.03M -331.45M -219.22M -129.12M -76.56M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 146.48M 180.77M 307.89M 290.88M 150.45M
Total Liabilities 138.49M 47.18M 264.39M 232.82M 98.07M
Shareholders' Equity 7.99M 133.58M 43.50M 58.06M 52.38M
Total Debt 107.01M 8.05M 210.14M 207.10M 72.14M
Cash & Equivalents 124.22M 152.60M 277.92M 273.87M 131.30M
Current Assets 132.83M 160.40M 295.36M 280.49M 139.11M
Current Liabilities 33.80M 40.73M 56.31M 27.58M 22.45M